Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment

The document reports on the safety of Baricitinib in adults with severe alopecia areata, based on data from two Phase III trials, BRAVE-AA1 and BRAVE-AA2. These trials followed participants over a median of 2.3 years, with some up to 4 years of treatment. The study found that Baricitinib was generally well-tolerated, with the most common adverse events being upper respiratory tract infections, headaches, and acne. Serious adverse events were infrequent. The trials included a substantial number of participants, enhancing the reliability of the findings. Overall, the long-term use of Baricitinib appears to be safe for treating severe alopecia areata.